Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

@article{Parving2012CardiorenalEP,
  title={Cardiorenal end points in a trial of aliskiren for type 2 diabetes.},
  author={H H Parving and Barry M. Brenner and John J V McMurray and Dick de Zeeuw and Steven M. Haffner and Scott Solomon and Nish Chaturvedi and Frederik Persson and Akshay S. Desai and Maria Nicolaides and Alexia Richard and Zhihua Xiang and Patrick C. Brunel and Marc Pfeffer},
  journal={The New England journal of medicine},
  year={2012},
  volume={367 23},
  pages={2204-13}
}
BACKGROUND This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 168 times over the past 90 days. VIEW TWEETS
350 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 350 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking The New England

  • JJ McMurray, J Ostergren, K Swedberg
  • Journal of Medicine Downloaded from nejm.org on…
  • 2013

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

  • Y Miao, D Dobre, HJ Heerspink
  • Diabetologia
  • 2011

sociation between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus , anemia , and CKD

  • FA Holtkamp, D deZeeuw, PA deGraeff
  • Am J Kidney Dis
  • 2011

Similar Papers

Loading similar papers…